Navigation Links
Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science
Date:3/17/2011

activator of cardiac myosin, was developed to address these limitations.

In this publication, the authors demonstrated that omecamtiv mecarbil binds to the myosin catalytic domain and acts by an allosteric mechanism to increase the transition rate of myosin into the strongly actin-bound force-generating state. Paradoxically, omecamtiv mecarbil inhibits adenosine 5'-triphosphate (ATP) turnover in the absence of actin, which suggests that it stabilizes an actin-bound conformation of myosin. In animal models, omecamtiv mecarbil increases cardiac function by increasing the duration of ejection without changing the rates of cardiac contraction. The authors concluded that cardiac myosin activation may provide a new therapeutic approach for patients with systolic heart failure.

"This ground-breaking publication underscores the quality and robustness of the science at our company which relates to the mechanics and biology of muscle function and that serves as the basis for our portfolio of drug candidates," stated Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "Over several years, our promising research has now resulted in multiple first-in-class compounds that may address unmet clinical needs in a broad array of indications and medical conditions associated with impaired muscle contractility."

Development Status of Omecamtiv Mecarbil

Omecamtiv mecarbil, a novel cardiac muscle myosin activator, has been the subject of a clinical trials program comprised of multiple Phase I and Phase IIa trials conducted under Cytokinetics' sponsorship. This program was designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of both intravenous and oral formulations of omecamtiv mecarbil for the potential treatment of heart failure across the continuum of care, in both hospital and outpatient settings. Two Phase IIa clinical trials of omecamtiv mecarbil from this program have been com
'/>"/>

Contact: Christopher Keenan
ckeenan@cytokinetics.com
415-505-2581
Cytokinetics, Inc.
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
(Date:9/19/2014)... NEW YORK , Sept. 19, 2014  An ... common forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) ... feet and legs, causing extreme muscle atrophy, weakness, and ... in the US and millions worldwide. CMT is a ... use of their legs, requiring mobility devices such as ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... Massachusetts , September 19, 2014 ... the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... of science and medical research in the field of ... Merck KGaA, Darmstadt, Germany , today ... Innovation (GGI) for 2014. The awards were announced during ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... an advanced,biomaterials company, announced today that it has ... Under the agreement, LifeNet Health will provide ... mixed with ETEX,s proprietary,calcium phosphate to form a ... EquivaBone(TM) in its Cambridge,facilities and market the product ...
... Corporation,(Nasdaq: IOMI ) today announced that it will ... markets open and hold a,conference call and live webcast ... 2008 at 1:30 p.m. Eastern Time., Conference Call ... Thursday, March 6 at 1:30 p.m.,Eastern Time via phone, ...
... /PRNewswire/ - BIKAM,pioneers in the discovery and ... of degenerative eye diseases and ocular disorders ... exclusive worldwide,collaboration and agreement to discover and ... Dalton Medicinal Chemistry will utilize their ...
Cached Biology Technology:ETEX and LifeNet Health, Inc. Enter Agreement 2Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6 2BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement 2
(Date:9/18/2014)... Worcester, Mass. A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, ... communicating creatures. , But by using a ... radically alter their behavior to suit their population. ... them are present, and act accordingly. , Once ... it may change from innocuous to pathogenic, or ...
(Date:9/18/2014)... is stored in DNA, tiny strands of nucleic acid ... To express this genetic data, our DNA is copied ... proteins that perform tasks in our cells. , ... RNA molecule. Unlike all other known RNAs, this molecule ... molecules are abundant, little has been known about how ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... a pretzel factory production line, with conveyer belts carrying the dough, ... Now imagine what would happen if pretzel dough started ... conveyor, misshapen, and sticking fast to the dough of the other ... mess could no longer be conveyed into the oven, the backup ...
... CRUZ, CA--An intricate three-way mating struggle first observed in ... in a distant relative, the European common lizard. The ... million years of evolution, yet they share behavioral and ... the males, according to new research published in the ...
... the University of Warwick have devised a means of ... in just a few seconds. Previous techniques have ... finger print and laboriously match them against a database ... entire detailed pattern of each print and transform the ...
Cached Biology News:Botched production of insulin molecule may lead to diabetes 2Botched production of insulin molecule may lead to diabetes 3Botched production of insulin molecule may lead to diabetes 4Three-way mating game of North American lizard found in distant European relative 2Three-way mating game of North American lizard found in distant European relative 3Three-way mating game of North American lizard found in distant European relative 4New technology identifies warped fingerprints at warp speed 2
... For use in Refrigerated Vapor Trap ... Vacuum Source (UVS) Models UVS400, UVS400A and ... polymer suitable for use for temperatures ranging ... has excellent thermal stability and does not ...
Acetate Plate Sealers 100/Box...
... demands the detection of very small amounts ... AXIMA-CFRplus with improved resolution (20,000) and mass ... confidence in protein identification. The AXIMA-CFRplus also ... sample target handling and the ability to ...
QCPN...
Biology Products: